Skip Navigation
Megan McArdle

Megan McArdle - Megan McArdle is a senior editor for The Atlantic who writes about business and economics. She has worked at three start-ups, a consulting firm, an investment bank, a disaster recovery firm at Ground Zero, and The Economist. More

Megan was born and raised on the Upper West Side of Manhattan, and yes, she does enjoy her lattes, as well as the occasional extra-dry skim-milk cappuccino. Her checkered work history includes three start-ups, four years as a technology project manager for a boutique consulting firm, a summer as an associate at an investment bank, and a year spent as sort of an executive copy girl for one of the disaster-recovery firms at Ground Zero … all before the age of 30.

While working at Ground Zero, Megan started Live From the WTC, a blog focused on economics, business, and cooking. She may or may not have been the first major economics blogger, depending on whether we are allowed to throw outlying variables such as Brad Delong out of the set. From there it was but a few steps down the slippery slope to freelance journalism. She has worked in various capacities for The Economist, where she wrote about economics and oversaw the founding of Free Exchange, the magazine's economics blog. She has also maintained her own blog, Asymmetrical Information, which moved to The Atlantic, along with its owner, in August 2007.

Megan holds a bachelor's degree in English literature from the University of Pennsylvania and an M.B.A. from the University of Chicago. After a lifetime as a New Yorker, she now resides in northwest Washington, D.C., where she is still trying to figure out what one does with an apartment larger than 400 square feet.

To Vaccinate or Not To Vaccinate

By Megan McArdle
Oct 30 2009, 11:04 AM ET Comment

Does the flu vaccine do any good?  In our November magazine, Shannon Brownlee and Jeane Lenzer suggested that the apparent beneficial effect might be due more to selection bias than to any actual impact of the injection:  people who get a flu shot are probably more conscientious about their health in many areas, which messes up your numbers.  The core problem seems to be that, unlike childhood illnesses, the groups most at risk from dying of flu, and therefore the most likely to be vaccinated, are often also the groups least likely to mount a good immune response to the vaccine--after all, the reason they're at risk is, in most cases, that their immune system can't take care of business. 

A science-loving friend sent the article to his brother, a public health researcher at a major university, and passes the commentary on to me:

I think there is a responsible debate about the benefits of population-wide influenza immunization (as opposed to the kooky fringe opponents to all childhood vaccinations)

Mainly it is a one of magnitude. mostly the debate concerns the ubiquitous phenomenon of more netbenefit accruing when you target higher risk groups. The more broadly a population vaccination program is, the smaller the net benefit. Likewise, the net benefit varies with how well the yearly vaccine matches the actual infecting strains. The latter may dramatically improve with some of the technology developed as part of producing this years H1N1 vaccine allowing them to choose the virus cocktail later.

And like the (especially) breast and prostate screening controversies, part of the debate is over whether one should confuse the public by airing the debate in public lest you scare off the high risk people who almost everyone would agree should get vaccinated/screened.

Some unknowns (or not well defined) things that affect recs about vaccination strategies:

1) the role of "herd immunity" - so broader vaccination in groups that don't directly benefit may, by breaking up transmission, benefit the high risk groups especially given:

2) the uncertain clinical significance of the diminished vaccine response in the high risk groups (older/sicker people don't make as many antibodies after vaccination but may still get substantial benefit) and this year

3) the fact that the current pandemic(with its risk of mutation and dramatic worsening) may overwhelm capacity makes any benefit from vaccination potentially worth going for as each increment in influenza illness burden could represent the straw that breaks the camels back from the point of view of health care capacity or even economic activity.

As you can imagine, lots of good modeling opportunities here to explore the impact of different levels of the unknowns.

I'm supposed to get a flu shot, because I have asthma, and flu usually turns into horrendous bronchitis.  But I may reconsider.


Presented by

More at The Atlantic

Greece Is on Pace for the Worst Recession in Modern History Why the Greek Recession Could Get Much Worse
Our Aging Prison Population: Should Criminals Die Free? Should Aging Prisoners Die Free?
The 10 Best and 10 Worst States for High-Tech Business The 10 Best States for High-Tech Business
Love Stinks: An Economic Manifesto Love Stinks: An Economic Manifesto
Adulthood, Delayed: What Has the Recession Done to Millennials? Adulthood, Delayed: The Recession and Millennials

Join the Discussion

After you comment, click Post. If you’re not already logged in you will be asked to log in or register.
blog comments powered by Disqus
Special Report
The Civil War National Portrait Gallery The Civil War
President Obama reflects on what Lincoln means to him and to America, in an introduction to our special issue. Read more ›
View All Correspondents

The Biggest Story in Photos

World Press Photo Contest 2012

Feb 15, 2012

Subscribe Now

SAVE 59%! 10 issues JUST $2.45 PER COPY

Facebook

Newsletters

Sign up to receive our free newsletters

(sample)

(sample)

(sample)

(sample)

Megan McArdle
from the Magazine

Why Companies Fail

GM’s stock price has sunk by a third since its IPO. Why is corporate turnaround so difficult…

The Graduates

Busted banking careers, crashed consultants, and shrunken incomes: the author attends her 10-year…

Romney’s Business

The Republican contender touts his business experience—but does it really matter?